Leren T P, Bakken K S, Rødningen O K, Gundersen K E, Sundvold H, Berg K, Tonstad S, Ose L
Avdeling for medisinsk genetikk, Ullevål sykehus, Blindern, Oslo.
Tidsskr Nor Laegeforen. 1997 Feb 20;117(5):678-81.
Familial hypercholesterolaemia is an autosomal dominant disorder characterized by hypercholesterolaemia, xanthomas and premature coronary heart disease. Treatment of hypercholesterolemia is effective and consists of dietary changes and lipid lowering drugs. Only a minor proportion of familial hypercholesterolaemia patients are adequately treated, however. One explanation for this is assumed to be the relatively vague clinical diagnostic criteria applied. Because familial hypercholesterolaemia is caused by a mutation in the gene encoding the low density lipoprotein (LDL) receptor, mutation analysis of this gene could form the basis for specific diagnosis. 29 different mutations in the LDL receptor gene have been found to cause familial hypercholesterolaemia among Norwegian patients, and a total of 681 patients from 322 unrelated families have been provided with a molecular genetic diagnosis. We conclude that the use of molecular genetic analysis is feasible, and should be used clinically.
家族性高胆固醇血症是一种常染色体显性疾病,其特征为高胆固醇血症、黄色瘤和早发性冠心病。高胆固醇血症的治疗是有效的,包括饮食改变和降脂药物。然而,只有一小部分家族性高胆固醇血症患者得到了充分治疗。对此的一种解释被认为是所应用的临床诊断标准相对模糊。由于家族性高胆固醇血症是由编码低密度脂蛋白(LDL)受体的基因突变引起的,对该基因进行突变分析可作为特异性诊断的基础。在挪威患者中,已发现低密度脂蛋白受体基因的29种不同突变会导致家族性高胆固醇血症,并且已经为来自322个无亲缘关系家庭的681名患者提供了分子遗传学诊断。我们得出结论,分子遗传学分析的应用是可行的,并且应该在临床上使用。